Compare Regeneron Pharmaceuticals Inc (REGN) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ProShares Ultra Semiconductors — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while ProShares Ultra Semiconductors trades at $99.6 (market cap $3.15B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 24.3× ProShares Ultra Semiconductors's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and ProShares Ultra Semiconductors for 29 Days on average.
| REGN | USD | |
|---|---|---|
Market Cap | $76.40B | $3.15B |
Volume | 626,381 | 333,862 |
Sector | Health | Leveraged / Inverse |
52-Week High | $852.03 | $113.53 |
52-Week Low | $557.73 | $43.19 |
Typical Hold Time | 107 Days | 29 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength, though RSI levels suggest potential overbought conditions. Recent corporate action includes a $0.13 dividend scheduled for September 2026. Support levels are established at $100-$102, with resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investment opportunity lies in the bullish technical setup and dividend yield, while risks include potential overbought conditions and lack of current financial metrics. Investors should await updated financial reports for fundamental validation of the current price level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
